Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report
Progyny (Nasdaq: PGNY) will report fourth quarter and full year 2025 results after market close on February 26, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Progyny (Nasdaq: PGNY) will report fourth quarter and full year 2025 results after market close on February 26, 2026.
The company will host a conference call at 4:45 p.m. ET and publish a press release before the call. Dial‑in numbers, passcode 265484, replay through March 5, 2026, and a live webcast/archive are available on the investor website.
Details
News Market Reaction – PGNY
On Feb 12, the day this news came out, PGNY closed 2.65% below the previous close.
Data tracked by StockTitan Argus for the Feb 12 session.
Key Figures
- Quarter end date
- December 31, 2025
- Quarterly period and full year end for reported results
- Earnings release date
- February 26, 2026
- Date PGNY will report Q4 and full-year 2025 results
- Conference call time ET
- 4:45 p.m. Eastern Time
- Scheduled start time of results conference call
- Conference call time PT
- 1:45 p.m. Pacific Time
- Corresponding Pacific Time for the call
- U.S. dial-in number
- 1.866.825.7331
- U.S. participants’ access number for the earnings call
- International dial-in
- 1.973.413.6106
- International participants’ access number for the call
- Call passcode
- 265484
- Passcode required to join the live and replay calls
- Replay available through
- March 5, 2026
- End date for telephone replay access
Previous Earnings Reports
-
Reported Q3 2025 growth, strong cash flow, raised full-year 2025 guidance.
-
Announced Q3 2025 earnings release date and conference call logistics.
-
Delivered strong Q2 2025 revenue and earnings, raised full-year guidance.
-
Secured $200M credit facility and guided Q2 results above prior expectations.
-
Posted record Q1 2025 revenue, margin expansion, and raised 2025 guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period and full year ended December 31, 2025, after the close of the market on Thursday, February 26, 2026.
The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.
Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode.
An audio replay of the call will be available through Thursday, March 5, 2026, and may be accessed by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international participants) with the passcode 265484.
A live webcast and archive of the call will be available from the Events and Presentations section of the Company’s website at http://investors.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.
For Further Information, Please Contact:
Investors:
James Hart
investors@progyny.com
Media:
Alexis Ford
media@progyny.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.